Ibogaine and its primary metabolite noribogaine act on hERG potassium channels in the heart — the same channels responsible for repolarizing cardiac muscle cells between beats. This action prolongs the QT interval on an electrocardiogram, which in susceptible individuals creates a window of vulnerability for a dangerous arrhythmia called Torsades de Pointes.
This pharmacological property is well-documented and entirely predictable. It is also why approximately 15% of applicants are declined after screening — not because ibogaine is uniquely dangerous, but because their baseline cardiac profile falls outside safe treatment parameters.
The critical distinction: every known ibogaine-related cardiac event has occurred in settings without proper pre-treatment screening. In patients who pass a full cardiac evaluation and are monitored with continuous telemetry, the risk picture changes dramatically.
Every MindScape patient completes all seven steps without exception. No shortcuts, no waivers.
Before you travel or commit to a treatment date, our medical team reviews your complete medical history, current medications, substance use history, and prior cardiac records. This remote review identifies any immediate disqualifiers and guides what testing is required.
The single most critical pre-screening test. A physician must interpret your 12-lead EKG for QTc interval length, QRS morphology, Brugada pattern, and other conduction abnormalities. QTc above 450ms is an absolute contraindication. The EKG must be performed at a certified facility within 30 days of your treatment date.
Complete metabolic panel (CMP), liver function tests, complete blood count (CBC), thyroid panel, and electrolyte levels. Electrolytes — particularly potassium and magnesium — directly affect QTc. Low potassium or magnesium independently prolongs the QT interval and must be corrected before treatment.
Every prescription medication, over-the-counter drug, herbal supplement, and recreational substance must be disclosed. Our physicians cross-reference your full medication list against known ibogaine interactions. Patients on SSRIs, opioids, antipsychotics, or QTc-prolonging agents cannot proceed until the interaction risk is fully resolved.
Upon arrival in Cozumel, the treating physician conducts a clinical cardiac examination — reviewing your EKG again, assessing vital signs, confirming electrolyte status, and performing a physical cardiovascular examination. Any change from your pre-screening status is evaluated before proceeding.
Cardiac telemetry monitoring begins before the first booster dose and continues uninterrupted through the full active experience and into the recovery phase. QTc, heart rate, rhythm, blood pressure, and oxygen saturation are tracked continuously. Any QTc prolongation exceeding 500ms triggers an immediate clinical protocol.
A final 12-lead EKG is performed before any patient is cleared for discharge. QTc must return to within baseline normal range. Patients remain under medical observation for a minimum of 48 hours post-treatment. No physician clearance means no departure.
Simplified 12-Lead ECG — QT Interval
The QT interval (highlighted) spans from the start of the QRS complex to the end of the T wave — measuring the heart's full electrical reset cycle.
When the QT interval stretches too long, the heart is vulnerable during that extended repolarization window. In rare cases, a second electrical impulse can arrive during this window and trigger Torsades de Pointes — a rapid, potentially life-threatening ventricular arrhythmia.
Ibogaine prolongs QTc in all patients to some degree. The question is where your baseline sits. A patient with a baseline QTc of 410ms may reach 440ms during ibogaine treatment — safely within range. A patient with a baseline of 460ms reaching 500ms is in dangerous territory.
Standard pre-treatment EKG threshold. Treatment proceeds under continuous monitoring.
Medical director reviews on case-by-case basis. May require electrolyte optimization and echocardiogram before proceeding.
Absolute contraindication. Patient is not treated, regardless of other clinical factors. Follow-up with cardiologist is recommended.
This list covers the most clinically significant interactions. Disclosing your complete medication history is mandatory — withholding information is the single greatest safety risk we encounter.
Long half-life and cumulative cardiac burden make concurrent ibogaine administration unsafe. Requires a medically supervised transition to a short-acting opioid for 7–14 days prior to treatment. We manage this process with you.
Risk of serotonin syndrome. Requires physician-supervised taper and full washout (minimum 2 weeks; 4–6 weeks for fluoxetine). Patients are not treated until clearance is confirmed.
Low prescribed doses may be manageable with physician guidance. High-dose or long-term benzodiazepine use requires a supervised taper before treatment. Ibogaine does not treat benzodiazepine dependence.
Sympathomimetic stimulants increase cardiac strain and must be fully discontinued prior to treatment. Prescription stimulants require a physician-directed taper. Recreational use must be disclosed.
Most antipsychotic medications significantly prolong the QTc interval. This is an absolute contraindication with no current protocol for management. Patients on antipsychotics cannot receive ibogaine at this time.
Azithromycin, clarithromycin, fluoroquinolones (ciprofloxacin, levofloxacin), and similar antibiotics extend the QTc interval additively. Must be fully cleared (5+ half-lives) before treatment begins.
Class I and III antiarrhythmics (amiodarone, sotalol, flecainide, quinidine) carry additive QTc prolongation risk that makes ibogaine administration unsafe. Requires cardiologist consultation before any consideration.
Strict contraindication due to risk of hypertensive crisis and serotonin syndrome. Irreversible MAOIs must be cleared for a minimum of 14 days. Full disclosure is required on intake.
Not an exhaustive list. Any medication that affects cardiac conduction, serotonin pathways, liver metabolism, or the central nervous system must be disclosed. Our medical team reviews every patient's complete medication list before any treatment decision is made.
These conditions are not automatic disqualifiers, but each requires individual evaluation by our medical director before treatment can proceed.
Any history of arrhythmia, heart failure, valve disorders, prior cardiac events, or structural heart disease requires an echocardiogram in addition to the standard 12-lead EKG. Each case is individually assessed by our medical director.
Ibogaine is primarily metabolized by the liver (CYP2D6 enzyme). Hepatitis, cirrhosis, or elevated liver enzymes significantly alter how the compound is processed. Full liver panel and, in some cases, hepatologist consultation is required.
Active or poorly controlled seizure disorders require careful individual evaluation. Stable, well-managed epilepsy with a low-risk antiepileptic regimen may be compatible with treatment on a case-by-case basis.
Ibogaine is an absolute contraindication during pregnancy with no exceptions. A pregnancy test is required for all patients who could be pregnant, completed within 72 hours of treatment.
Myocardial infarction, cardiac surgery, or significant arrhythmia within the prior six months is a contraindication until full cardiologist clearance has been obtained and documented.
Proper screening prevents cardiac events. Proper emergency preparedness ensures that if the unexpected occurs, the response is immediate.
Medical-grade defibrillator immediately accessible throughout every treatment session.
First-line intervention for QTc prolongation and Torsades de Pointes. Ready for immediate IV administration.
Epinephrine, atropine, lidocaine, amiodarone, adenosine, and ACLS-grade resuscitation medications stocked on-site.
All treating physicians hold Advanced Cardiovascular Life Support certification. Not nurses — attending physicians.
Real-time cardiac rhythm and QTc tracking displayed at the patient bedside and nursing station throughout treatment.
Signed agreement with a cardiac-capable hospital in Cozumel. Transfer capability is within 20 minutes with a standing protocol.
MindScape treats one patient at a time per physician. Your physician is physically present throughout your entire treatment window — not on-call, not remotely available. Present. The registered nursing team maintains continuous bedside monitoring throughout the active experience and recovery period.
Ibogaine is safe for patients who pass a comprehensive cardiac screening. It is not safe for patients with undetected cardiac abnormalities. This is precisely why mandatory pre-treatment EKG and cardiac evaluation exists. MindScape Retreat has treated over 900 patients with zero cardiac events. Every one of them passed our full screening protocol before any treatment began.
The QT interval is a measurement on an electrocardiogram that represents the time your heart takes to electrically reset between beats. 'QTc' is the corrected value, adjusted for heart rate. When this interval becomes abnormally long (above 450ms for our purposes), the heart is vulnerable to a specific dangerous arrhythmia called Torsades de Pointes. Ibogaine prolongs QTc through its effect on hERG potassium channels. This is manageable when the baseline QTc is within safe limits and monitoring is continuous throughout treatment.
Not directly. Methadone requires a transition protocol — a medically supervised bridge to a short-acting opioid for 7 to 14 days before ibogaine treatment begins. This is due to methadone's long half-life and its own independent QTc-prolonging effect. MindScape's clinical team manages this transition process with patients who want to pursue ibogaine. It requires more planning, not more risk.
If your pre-screening EKG shows QTc prolongation above 450ms or any other significant cardiac finding, we will not proceed with treatment. We will communicate this clearly, explain the finding, and suggest you follow up with a cardiologist. In some cases, if the abnormality is addressable (electrolyte correction, medication adjustment), a repeat EKG after resolution may be appropriate. Patient safety always takes precedence over any other consideration.
Cardiac telemetry begins before the first dose is administered and continues for a minimum of 24 hours after the flood dose. In practice this means continuous monitoring throughout the active experience, through the resolution phase, and into early recovery. A follow-up EKG is performed before any patient is cleared for discharge.
SSRIs, SNRIs, MAO inhibitors, methadone, antipsychotics, stimulants, and QTc-prolonging antibiotics all require either a supervised taper or a sufficient washout period before ibogaine can be safely administered. Benzodiazepines at high doses also require careful management. This list is not exhaustive — every medication you take must be disclosed and reviewed by our medical team. Never stop any medication abruptly without physician guidance.
The screening process is not a hurdle — it is the foundation of a safe outcome. Start with a confidential intake review. Our medical team will assess your history, review your medications, and give you an honest answer about whether ibogaine is right for you.